Estravís, Miguel http://orcid.org/0000-0001-9788-4540
García-Sánchez, Asunción http://orcid.org/0000-0002-9655-4918
Martin, Maria J. http://orcid.org/0000-0002-3687-2789
Pérez-Pazos, Jacqueline http://orcid.org/0000-0002-2023-781X
Isidoro-García, María http://orcid.org/0000-0002-9013-9422
Dávila, Ignacio http://orcid.org/0000-0001-8485-5513
Sanz, Catalina http://orcid.org/0000-0003-2974-0873
Funding for this research was provided by:
Instituto de Salud Carlos III (PI17/00818, PI20/00268, RD16/0006/0019)
Consejería de Educación, Junta de Castilla y León (IES161P20)
Gerencia Regional de Salud, Junta de Castilla y León (GRS2156/A/20)
Universidad de Salamanca
Article History
Received: 13 January 2022
Accepted: 29 August 2022
First Online: 12 September 2022
Declarations
:
: I.D. reports personal fees from Novartis, Sanofi, GSK, Astra-Zeneca, LETI, and Teva, and grant and personal fees from Thermo Fisher outside the submitted work. The rest of the authors declare no conflict of interest.
: The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.